Lawmakers target fiscal cliff's provision aiding Amgen for elimination

Published on January 28, 2013 at 6:13 AM · No Comments

The fiscal cliff legislation approved earlier this month excluded Amgen's Sensipar, which is used by kidney dialysis patients, from Medicare price controls for an additional two years.

Los Angeles Times: Lawmakers Seek To Repeal 'Fiscal-Cliff' Provision Aiding Amgen
A bipartisan group of U.S. lawmakers is seeking to repeal a Medicare-pricing provision in the recent "fiscal-cliff" deal in Congress that benefits Thousand Oaks biotech giant Amgen Inc. Legislation to eliminate the exemption for a class of drugs, including Amgen's Sensipar, that are used by kidney dialysis patients, was filed this week by U.S. Rep. Peter Welch (D-Vt.). The fiscal cliff legislation approved this month excluded these oral medications from Medicare price controls for an additional two years (Terhune, 1/25).

Meanwhile, Sen. Orrin Hatch, R-Utah, issues list of five Medicare and Medicaid changes that he predicts would draw bipartisan support --  

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment